LENZ Therapeutics Inc. (LENZ)
NASDAQ: LENZ
· Real-Time Price · USD
28.89
-0.11 (-0.38%)
At close: Jun 16, 2025, 3:59 PM
28.82
-0.24%
After-hours: Jun 16, 2025, 04:04 PM EDT
Company Description
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.
Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.
The company is headquartered in Del Mar, California.
LENZ Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 22, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Evert B. Schimmelpennink |
Contact Details
Address: 445 Marine View Avenue Solana Beach, California United States | |
| Website | https://www.lenz-tx.com |
Stock Details
| Ticker Symbol | LENZ |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001815776 |
| CUSIP Number | 52635N103 |
| ISIN Number | US52635N1037 |
| Employer ID | 84-4867570 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Evert B. Schimmelpennink | President, Chief Executive Officer, Secretary & Director |
| Daniel R. Chevallard CPA | Chief Financial Officer |
| Breianna Bowen | Vice President of Human Resources |
| David Choromanski | Vice President of Marketing |
| Domenick Porfidia | Vice President of Sales |
| James W. McCollum | Co-Founder & Director |
| Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations |
| Marc G. Odrich M.D. | Chief Medical Officer |
| Melissa Rosness | Senior Vice President of Manufacturing Operations |
| Shawn Olsson | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Jun 12, 2025 | 4 | Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 11, 2025 | 4 | Filing |
| Jun 10, 2025 | 8-K | Current Report |